The risks of direct-to-consumer pharmaceutical advertising and Big Pharma
In 2002, prescribing risperidone meant fighting through layers of resistance. I had to argue with formulary doctors, armed with a special copy of the New England Journal of Medicine article where my own name was highlighted, just to gain permission. That was the level of scrutiny these drugs once demanded. The article itself was not obscure, it was a landmark trial demonstrating risperidone’s efficacy in children with autism spectrum disorders.
Yet …
The risks of direct-to-consumer pharmaceutical advertising and Big Pharma









![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)


![Why physicians pay more in taxes and how to reclaim your income [PODCAST]](https://kevinmd.com/wp-content/uploads/65a06f47-06d1-44f6-b074-deb9a2d19a25-190x100.jpeg)




